Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Hoshi Iryo-Sanki Co., Ltd. specializes in the manufacturing and distribution of medical equipment and services, primarily focusing on advanced diagnostic imaging systems and surgical instruments. The company operates predominantly in Japan, with a growing presence in Southeast Asia, leveraging its strong R&D capabilities to maintain a competitive edge in innovation and quality.
Hoshi Iryo-Sanki generates revenue through the sale of high-margin medical equipment and ongoing service contracts, which provide stable recurring income. The company's competitive advantages include proprietary technology, a strong brand reputation in Japan, and established relationships with hospitals and healthcare providers.
Changes in healthcare spending in Japan and Southeast Asia
Regulatory approvals for new medical devices
Technological advancements in diagnostic imaging
Competitive pricing strategies from key rivals
Technological disruption from emerging medical technologies such as AI and telemedicine
Regulatory changes impacting medical device approvals and reimbursement policies
Increased competition from global players entering the Japanese market
Potential pricing pressures from low-cost manufacturers in Asia
Low liquidity risk due to a current ratio of 3.17, but reliance on consistent cash flow to fund R&D
Potential pension obligations impacting long-term financial health
moderate - As a healthcare equipment provider, Hoshi Iryo-Sanki's revenues are somewhat insulated from economic downturns, but overall healthcare spending can be influenced by GDP growth.
Interest rates affect the company's cost of capital for financing R&D and expansion. Higher rates could dampen investment in new technologies and reduce demand for capital-intensive medical equipment.
minimal - The company maintains a low debt-to-equity ratio of 0.06, indicating limited reliance on credit markets.
value - The low price-to-book ratio of 0.7 suggests potential undervaluation, appealing to value investors.
low - The company has historically shown low volatility, with a beta below 1.0.
